The company will push through with an accelerated approval application for odronextamab in follicular lymphoma, leaving ...

Credit: kirisa99 via Getty Images. US-based startup Bambusa Therapeutics has secured $90m in Series A financing to advance its pipeline of bispecific antibodies for immunological and inflammatory ...

Binod Dhakal, MD, MS, discussed the use of bispecific antibodies and chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma treatment. Targeted Therapies in Oncology: How has ...

Weave (NYSE: WEAV), a leading all-in-one customer experience and payments software platform for small and medium-sized healthcare businesses, today announced an integration with Practice Fusion, a ...

For more information, please contact: Johan Löf, founder and CEO, RaySearch Laboratories AB (publ) Telephone: + 46 (0) 8 510 530 00 [email protected] hellocare.ai, a leader in AI-assisted ...

Linvoseltamab is a bispecific antibody targeting B-cell maturation antigen ... to address therapeutic challenges and improve patient outcomes. The FDA accepted Regeneron’s BLA resubmission for ...

In collaboration, Amgen (NASDAQ:AMGN) is initiating a Phase III mCRPC study of xaluritamig (STEAP1xCD3), and Johnson & Johnson is conducting Phase I studies of two CD28 bispecific antibodies. Xencor's ...

In collaboration, Amgen (NASDAQ:AMGN) is initiating a Phase III mCRPC study of xaluritamig (STEAP1xCD3), and Johnson & Johnson is conducting Phase I studies of two CD28 bispecific antibodies.

which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics ...

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and ...